NO20021986L - Sodium 2- (4,6-dimethyl-pyrimidin-2-yloxy) -3- (2- (3,4-dimethoxyphenyl) ethoxy) -3,3-diphenylpropionate and its use as an endothelin antagonist - Google Patents

Sodium 2- (4,6-dimethyl-pyrimidin-2-yloxy) -3- (2- (3,4-dimethoxyphenyl) ethoxy) -3,3-diphenylpropionate and its use as an endothelin antagonist

Info

Publication number
NO20021986L
NO20021986L NO20021986A NO20021986A NO20021986L NO 20021986 L NO20021986 L NO 20021986L NO 20021986 A NO20021986 A NO 20021986A NO 20021986 A NO20021986 A NO 20021986A NO 20021986 L NO20021986 L NO 20021986L
Authority
NO
Norway
Prior art keywords
diphenylpropionate
dimethoxyphenyl
yloxy
pyrimidin
ethoxy
Prior art date
Application number
NO20021986A
Other languages
Norwegian (no)
Other versions
NO20021986D0 (en
Inventor
Rolf Jansen
Original Assignee
Basf Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Basf Ag filed Critical Basf Ag
Publication of NO20021986L publication Critical patent/NO20021986L/en
Publication of NO20021986D0 publication Critical patent/NO20021986D0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/34—One oxygen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Oppfinnelsen vedrører en forbindelse med formel (l) i en fast krystallinsk form og anvendelse derav som en blandet ETA/ETB-endothelinreseptorantagonist.The invention relates to a compound of formula (I) in a solid crystalline form and its use as a mixed ETA / ETB endothelin receptor antagonist.

NO20021986A 1999-10-27 2002-04-26 Sodium 2- (4,6-dimethyl-pyrimidin-2-yloxy) -3- (2- (3,4-dimethoxyphenyl) ethoxy) -3,3-diphenylpropionate and its use as an endothelin antagonist NO20021986D0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19951671A DE19951671A1 (en) 1999-10-27 1999-10-27 2- (4,6-Dimethyl-pyrimidin-2-yloxy) -3- (2- (3,4-dimethoxyphenyl) ethoxy) -3,3-diphenylpropionic acid sodium salt and its use as an endothelin antagonist
PCT/EP2000/010202 WO2001030767A1 (en) 1999-10-27 2000-10-17 Sodium 2-(4,6-dimethyl-pyrimidin-2-yloxy)-3-(2-(3,4-dimethoxyphenyl)ethoxy)-3,3-diphenylpropionate and use thereof as endothelin antagonist

Publications (2)

Publication Number Publication Date
NO20021986L true NO20021986L (en) 2002-04-26
NO20021986D0 NO20021986D0 (en) 2002-04-26

Family

ID=7927001

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20021986A NO20021986D0 (en) 1999-10-27 2002-04-26 Sodium 2- (4,6-dimethyl-pyrimidin-2-yloxy) -3- (2- (3,4-dimethoxyphenyl) ethoxy) -3,3-diphenylpropionate and its use as an endothelin antagonist

Country Status (17)

Country Link
EP (1) EP1228047A1 (en)
JP (1) JP2003512460A (en)
KR (1) KR20020047301A (en)
CN (1) CN1384822A (en)
AU (1) AU1272701A (en)
BG (1) BG106700A (en)
BR (1) BR0015112A (en)
CA (1) CA2389012A1 (en)
CZ (1) CZ20021485A3 (en)
DE (1) DE19951671A1 (en)
HU (1) HUP0203476A3 (en)
IL (1) IL149312A0 (en)
MX (1) MXPA02004071A (en)
NO (1) NO20021986D0 (en)
SK (1) SK5962002A3 (en)
TR (1) TR200201169T2 (en)
WO (1) WO2001030767A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2656017T3 (en) 2004-06-24 2018-02-22 Vertex Pharmaceuticals Incorporated Conveyor modulators of the ATP binding cassette

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19636046A1 (en) * 1996-09-05 1998-03-12 Basf Ag New carboxylic acid derivatives, their production and use as mixed ET¶A¶ / ET¶B¶ receptor antagonists

Also Published As

Publication number Publication date
BG106700A (en) 2003-02-28
AU1272701A (en) 2001-05-08
CA2389012A1 (en) 2001-05-03
CN1384822A (en) 2002-12-11
HUP0203476A2 (en) 2003-05-28
SK5962002A3 (en) 2002-09-10
KR20020047301A (en) 2002-06-21
IL149312A0 (en) 2002-11-10
DE19951671A1 (en) 2001-05-03
BR0015112A (en) 2002-10-29
CZ20021485A3 (en) 2003-06-18
TR200201169T2 (en) 2002-09-23
WO2001030767A1 (en) 2001-05-03
JP2003512460A (en) 2003-04-02
HUP0203476A3 (en) 2003-07-28
EP1228047A1 (en) 2002-08-07
MXPA02004071A (en) 2002-10-11
NO20021986D0 (en) 2002-04-26

Similar Documents

Publication Publication Date Title
NL350075I2 (en)
HK1099292A1 (en) Piperazinylpyrazine compounds as agonist or antagonist of serotonin 5ht-2 receptor
DK1337518T3 (en) Piperazinylpyrazine Compounds as Antagonists of the Serotonin-5-HT2 Receptor
TR200201874T2 (en) New compounds and compositions as protease inhibitors.
AP9901442A0 (en) 4-(2-Keto-1-benzimidazolinyl) piperidine compounds as orl1-receptor agonists.
YU39803A (en) Piperazinylpyrazine compounds as agonist or antagonist of serotonin 5ht-2-receptor
RS51444B (en) Lactam-containing compounds and derivatives thereof as factor xa inhibitors
SE9702773D0 (en) Novel compounds
TR200000786T2 (en) Vitronectin receptor antagonist
BG104447A (en) Biphenylamidine derivatives
TR200201128T2 (en) Tetrahydrothiopyraniphalazinone derivatives as PDE4 inhibitors.
MY128164A (en) Compounds
IL146543A0 (en) Inhibitors of metalloproteinases
TR200101654T2 (en) Vitronectin receptor antagonists
HRP20010630B1 (en) 4-heterocyclysulfonamidyl-6-methoxy-5-(2-methoxy-phenoxy)-2-pyridyl-pyrimidine derivatives, their preparation and use as endothelin receptor antagonists
DE60216948D1 (en) 4'-methansulfonylbiphenylderivate als hochselektive cyclooxygenase-2-inhibitoren
NO20021986L (en) Sodium 2- (4,6-dimethyl-pyrimidin-2-yloxy) -3- (2- (3,4-dimethoxyphenyl) ethoxy) -3,3-diphenylpropionate and its use as an endothelin antagonist
IT1316994B1 (en) USE OF PIPERIDINE BENZODERIVATES AS FUNGICIDES.
BR9806875A (en) Process for the preparation of a compound.
AR024797A1 (en) CRYSTALLINE FORM III OF THE N- (4- (5-DIMETHYLAMINONAFTALEN-1-SULPHONYLAMINE) PHENYL) -3-HYDROXI-2,2-DIMETHYLPROPIONAMIDE
DE60102231D1 (en) CRF RECEPTOR ANTAGONISTS AND RELATED METHODS
EP1533312A4 (en) Hetero-bicyclic compounds
NO20004075L (en) Substituted pyrimidin-2-yloxy-carboxylic acid derivatives, their preparation and their use as endothelin antagonists
FR2852977B1 (en) NOVEL COMPOSITION BASED ON LEGUMINOUS STARCH FOR THE ENNOBLICATION OF MATERIALS, ESPECIALLY FOR TEXTILE USE
IT1306200B1 (en) VULCANIZABLE COMPOSITIONS OF FLUOROELASTOMERS.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application